Background: Human epidermal growth factor receptor 2 (HER2) overexpression has been linked to hormoneindependent prostate cancer (HIPC) progression. Its clinical value and correlation with therapy is not defined.
introduction
Prostate cancer (PC) is the second leading cause of death in men from cancer. Despite the availability of local treatment with radical prostatectomy or radiotherapy, many patients develop disease relapse after primary therapy. The first sign of PC recurrence is often heralded by an increase of serum prostate-specific antigen (PSA) levels and is known as biochemical relapse. Subsequently, patients can develop clinical relapse of the disease typically featuring bone metastases [1] . Initially, the majority of metastatic PC patients respond to antiandrogen therapy, having a hormone-dependent status. PC, however, progresses despite androgen withdrawal, transforming into a hormone-independent status. Docetaxel-based chemotherapy has recently been shown to improve survival of patients with metastatic hormoneindependent PC and has become a standard treatment in this clinical situation [2, 3] . Approximately half of patients do not respond to docetaxel, however, and survival for patients with symptomatic hormone-refractory PC is low. For this reason, a better understanding of the molecular mechanisms related to hormone-independent progression and mechanisms of response or resistance to docetaxel would be of interest to select those patients more likely to derive a clinical benefit and, also, to design combination strategies rationally that might improve therapeutic results.
The c-erbB-2 gene [human epidermal growth factor receptor 2 (HER2)] is a member of the family of oncogenes associated with tyrosine protein kinase activity. HER2 has been proposed as a survival factor for PC cells in the absence of androgens [4] [5] [6] [7] [8] [9] . Overexpression of HER2 promotes the activation of the androgen receptor (AR) and enhances the binding of AR to the promoters of androgen-regulated genes [5] . Overexpression of HER2 also causes the activation of the PI3k/AKT pathways and the promotion of cell proliferation and survival [10, 11] . In PC patients, HER2 overexpression is found mainly in those patients who have become resistant to hormonal ablation [6, 7, [12] [13] [14] [15] [16] . Moreover, HER2 expression in tissue samples of hormone-independent PC patients has been associated with lower survival [17, 18] . Therefore, HER2 inhibition has become an attractive treatment strategy for hormone-refractory PC patients [19] [20] [21] [22] [23] . The efficacy of this strategy, however, has not been clinically proved to date.
HER2 oncoprotein is a 185-kDa transmembrane receptor (p185), with intracellular, transmembrane and extracellular domains (ECDs). The tyrosine kinase activity is associated with the intracellular domain. The ECD of the HER2 oncoprotein can be proteolytically cleaved from the intact receptor and released as a soluble molecule with a molecular mass of 105 kDa [24] [25] [26] . The ECD can be detected in the serum of patients with PC and its increase has been associated with metastatic hormone-independent disease stage [27] .
In this study, we show that circulating serum HER2 ECD levels are associated with the extension of the disease and a poor clinical outcome in patients with hormone-independent PC treated with docetaxel-based chemotherapy. Moreover, elevated levels of HER2 ECD correlate with 2+/3+ HER2 expression in hormone-independent PC tumor biopsies and may be useful to select patients for HER2-targeted therapy.
materials and methods patients
Patients with metastatic hormone-independent PC receiving first-line docetaxel-based chemotherapy were included in the study and were prospectively tested for HER2 ECD in serum before and during treatment. Hormone-independent progression was defined as evidence of disease progression (PSA increase on two consecutive measurements 2 weeks apart in addition to either new lesions on bone scan or increase in the size of measurable lesions) in the presence of castrate levels of testosterone (<50 ng/ml) after previous therapy with androgen suppression and progression to antiandrogen withdrawal. A histologically proven adenocarcinoma of the prostate and a patient Eastern Cooperative Group performance status (PS) of 0-2 were required for inclusion in the study. Patients who received antiandrogen therapy with flutamide or biclutamide had to demonstrate rising PSA levels 6 weeks after antiandrogen withdrawal. Patients who had not undergone orchiectomy were required to continue gonadal ablation with luteinizing hormone-releasing hormone analogue.
Pretreatment evaluation included a complete medical history, physical examination, bone scan, computed tomography (CT) of the abdomen and pelvis, and laboratory studies, including PSA, testosterone, cell blood count and biochemistry. Follow-up included physical examination and laboratory studies [complete blood count, PSA, alkaline phosphatase (AP) and lactate dehydrogenase (LDH)], before each cycle of chemotherapy and every 3-4 weeks after treatment was stopped. Bone scan and CT (if measurable disease) were carried out after the third and sixth cycle of therapy or when clinically indicated.
Patient recruitment began in August 2002. Based on docetaxel (Taxotere; Sanofi-Aventis) phase II reported studies in hormone-independent prostate cancer (HIPC) [28] [29] [30] [31] 
serum HER2 ECD levels
Serum HER2 ECD levels were determined using the automated Advia Centaur HER-2 assay (Siemens Medical Solutions Diagnostics, Tarrytown, NY). This test was performed by a two-sandwich chemoiluminometric assay using two monoclonal antibodies: acridinium ester-labeled mouse TA-1 and fluorescein-labeled mouse NB-3. These two monoclonal antibodies are specific for unique epitopes on the ECD of HER2. The chemiluminometric reaction is initiated after the addition of acid and base reactive. The relative light units are directly proportional to the quantity of HER2 antigen in serum.
tissue specimens
Hormone-dependent PC tissue was obtained by either prostate fine-needle biopsy or radical prostatectomy. Hormone-independent PC tissue was obtained by transuretral resection (prostate), lymph node biopsy (lymph node metastases) and bone marrow biopsy (bone metastases). The bone marrow specimens used in this study had been fixed with 4% buffered formalin and then decalcified using the chelating agent EDTA. A 10% EDTA solution was used in distilled water (pH 7.4) for a period of 2 weeks. Then the tissues were embedded in paraffin. All tissue specimens (prostate, lymph node and bone marrow) were cut (2-4 lm), mounted on sylanizated slides and then deparaffinized in xylene followed by immersion in ethanol and rehydrated previously to inmunohistochemistry.
HER2 immunohistochemistry
Available hormone-dependent and hormone-independent PC tissue specimens from patients included in this study were stained for HER2 using the HercepTest immunohistochemistry kit (Dako, Carpinteria, CA) according to the manufacturer's procedures. HER2 cell membrane-specific immunostaining was classified into categories 0 to +3. Score 0 was defined as undetectable staining or membrane staining in <10% of the tumor cells. Score +1 was defined as a weak incomplete membrane staining detected in >10% of the tumor cells. Score +2 was considered as a weak to moderate complete membrane staining observed in >10% of the tumor cells. Finally, score +3 was defined as a moderate to strong complete membrane staining observed in >10% of the tumor cells.
FISH
The Vysis INC Fluorescence in situ hybridization (FISH) (Downers Grove, IL) system was used. This procedure consists of two different probes, one with the centromeric a-satellite probe specific for chromosome 17 (spectrum green) and a locus-specific probe for HER2 gene (spectrum orange). The Vysis probe was provided in denaturated state as single-strand DNA. Results were analyzed in a fluorescent Nikon (Eclipse 600) microscope. HER2 amplification was calculated dividing both the most frequent and largest values for HER2 spots/nucleus by the most frequent values of chromosome 17 centromere spots/nucleus. A minimum of 60 nuclei were scored, and amplification was considered when the ratio was ‡2. The median prechemotherapy HER2 ECD serum level was 12.4 ng/ml (range 4.6-79.9). Forty-five patients (65.2%) were considered to have low serum HER2 ECD levels (£15 ng/ml) and 24 patients (34.8%) had high serum HER2 ECD levels (>15 ng/ml). As shown in Table 2 , serum HER2 ECD levels were significantly associated with the number of bone metastases (P = 0.002), PSA (P = 0.016), disease localization (P = 0.04) and LDH (P = 0.001). Serum HER2 ECD levels were also associated with PSA response to docetaxel (Table 3) . When serum HER2 ECD levels were grouped (£15 versus >15 ng/ml) and analyzed as a binarized qualitative variable (v 2 test), significant statistical association emerged between HER2 ECD serum levels and PSA response to docetaxel (P = 0.046). Fifty-eight percent of the patients with low HER2 ECD showed a PSA response to docetaxel, while only 36% of the patients with high HER2 levels responded to the same therapy (P = 0.046).
Furthermore, high (>15 ng/ml) HER2 ECD serum levels were significantly associated with a lower time to PSA progression ( Figure 1A Besides HER2 ECD serum levels, other variables were associated with PSA disease progression and OS. Hemoglobin (P = 0.016), number of bone metastases (P = 0.006), duration of hormone dependence (P = 0.016) and LDH (P = 0.036) were predictive factors for time to PSA progression. For OS, visceral metastasis versus nonvisceral metastasis (P = 0.002), PS at study entry of ‡1 versus 0 (P = 0.006), number of bone metastases (P = 0.002), hemoglobin (P < 0.0001), AP levels (P < 0.0001) and LDH serum levels (P = 0.002) emerged as prognostic factors.
We also analyzed if docetaxel treatment frequency (once every 3 weeks versus weekly administration) had an impact on the clinical outcome of patients. Patients that 
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received docetaxel once every 3 weeks had a longer median time to PSA progression (4.3 months; 95% CI 3.0-5.5) when compared with patients that received weekly docetaxel (3.5 months; 95% CI 1.9-5.1). Also a longer OS in the group of patients that received docetaxel once every 3 weeks (12.9 months; 95% CI 8.1-17.7) when compared with patients that received weekly docetaxel (9.3 months; 95% CI 7.5-11.4) was detected. These differences, however, were not statistically significant (P = 0.126 and P = 0.104, respectively).
In the multivariate analysis for time to PSA progression and OS, HER2 ECD serum levels emerged as an independent prognostic factor for both time to PSA progression (P = 0.015) and OS (P = 0.007). Patients with high HER2 ECD (>15 ng/ml) levels had a HR for PSA progression of 2.82 (95% CI 1.22-6.50) when compared with patients with low HER2 ECD (£15 ng/ml) levels. Similarly patients with high HER2 ECD had a HR for death of 3.24 (95% CI 1.38-7.59) when compared patients with those with low HER2 ECD.
Furthermore, we analyzed serum HER2 ECD level changes during docetaxel therapy. Of the 22 patients with high baseline levels of HER2 ECD and with HER2 ECD follow-up during therapy, only two patients showed a HER2 ECD decrease ‡50% and three patients a HER2 ECD decrease ‡25% during docetaxel treatment. No statistical association between PSA response to docetaxel and HER2 ECD serum level behavior during therapy was observed. In patients with low baseline HER2 ECD levels, no significant changes were observed during therapy.
association between HER2 tissue expression and HER2 ECD serum levels From the 69 patients tested for baseline serum HER2, 19 hormone-independent PC tissue specimens were available from 17 patients. In two patients, hormone-independent PC tissue from two different sites was analyzed: prostatic tissue and supraclavicular lymph node metastatic tissue in one patient and prostatic tissue and brain metastatic tissue in the other. Furthermore, there were eight matched hormone-dependent and hormone-independent PC tissue specimens. Table 4 shows the results of HER2 hormone-dependent/HIPC tissue staining and serum HER2 ECD levels of the screened patients. None of the hormone-dependent PC tissues overexpressed HER2. Of the 17 hormone-independent patients, six (35.3%) overexpressed HER2 (score +2, +3) and the remaining 11 (64.7%) did not (score 0, +1). The two patients with hormone-independent tissue from two different sites also stained negatively for HER2. Figure 2 shows two hormoneindependent tissue specimens, one positive ( Figure 2A ) and the other negative ( Figure 2B ) for HER2 tissue staining.
Overall, there were eight matched pairs of cases where both hormone-dependent and hormone-independent PC tissue from the same patient was available for HER2 testing. Five (62.5%) matched pairs were also HER2 negative, and in three (37.5%) matched pairs the hormone-dependent tissue was negative and the hormone-independent tissue was HER2 positive. Furthermore, HER2 PC tissue expression was significantly related to HER2 ECD serum expression (t-test). Patients with negative HER2 tissue expression had serum HER2 ECD levels of 10.5 6 2.7 ng/ml and patients with positive HER2 tissue expression had serum HER2 ECD levels of 30.5 6 24.8 ng/ml (P = 0.016). Of note, all the positive HER2 tissue patients had serum HER2 ECD levels >15 ng/ml and all negative HER2 tissue patients had serum HER2 ECD levels £15 ng/ml.
We also analyzed the positive (score +2, +3) HER2 immohistochemical hormone-independent tumors for evidence of genomic amplification. In the tissue specimens analyzed by FISH, genomic amplification was not detected in any of them.
discussion
In this study, we show that elevated HER2 ECD serum levels are associated with the progession of disease and an aggressive original article Annals of Oncology clinical outcome. HER2 ECD levels also correlate with the overexpression of HER2 in patients' biopsies, suggesting that the determination of HER2 ECD in serum reflects the HER2 status in the hormone-independent tumor. The ECD of HER2 is shed into the circulation and can be elevated in the serum of men with PC [27, 32] . Osman et al. [27] reported that HER2 ECD levels increased during the natural history of PC in 279 patients in different stages of disease and hormone sensitivity. In this study, 13.3% of patients reached HER2 ECD levels superior to 14 ng/ml and correlated with risk of death. In the subgroup of patients with metastatic hormone-independent disease (n = 33), this percentage was 33.3%. In our study, high HER2 ECD (>15 ng/ ml) levels were associated with adverse clinical characteristics, and a lower PSA response rate, PSA progression-free survival and survival in a specific population of hormone-independent PC patients treated with docetaxel-based chemotherapy.
In PC patients, a cut-off for evaluating HER2 ECD levels is not established. For that reason, we analyzed HER2 ECD as a continuous variable. We also established a cut-off level of 15 ng/ml based on previous published data of our group in HER2 ECD determinations in patients with different tumor types and healthy donors [33] . In the present study, correlation of HER2 ECD with clinical outcome and with HER2 expression in tumor biopsies was observed in both cases. A larger prospective study of PC patients would be needed, however, to establish a cut-off level of HER2 ECD that may have clinical prognostic implications. Different published studies have shown that the expression of HER2 is linked to the transition from hormone-dependent to hormone-independent status [6, 7, [12] [13] [14] [15] [16] . We observed here that 37.5% of HIPC biopsies overexpress HER2, considered as 2+/3+ staining by immunohistochemistry. Also, consistent with other published studies, we did not observe HER2 gene amplification by FISH in patients that immunohistochemically overexpressed HER2. In this sense, the transcriptional and post-transcriptional mechanisms that might be responsible for increased HER2 transcript and protein in PC cells are not well known [34] .
Identification of biological markers of response to chemotherapy or biological therapies is particularly difficult in HIPC, especially because metastatic hormone-independent tissue is rarely accessible. In that sense, the strong correlation observed here between serum HER2 ECD levels and HER2 tissue expression may be a result of potential clinical interest. Our data indicate that patients with high levels of HER2 ECD present an adverse clinical outcome. In our series, HER2 ECD level is an independent prognostic factor for PSA progression and survival. In that sense, this marker emerged as a potential new prognostic factor in HIPC patients. Furthermore, HER2 ECD may also have a predictive value of response to docetaxel since an association between HER2 levels and docetaxel response was observed. The outcome of patients with high HER2 is very poor, with only 36% showing a response to docetaxel, and a median time to progression and survival of 2.4 and 8.2 single months, respectively. In this group Annals of Oncology original article of patients, it would be of interest to investigate different therapeutic strategies. Previous preclinical studies in PC cancer models showed antitumor activity of the anti-HER2 monoclonal antibodies, both transtuzumab and pertuzumab. Trastuzumab [35, 36] increased the antitumor activity of taxanes in hormone-independent xenografts; and pertuzumab [37] inhibited prostate tumor growth in animal models. Anti-HER2-targeted therapy, however, has not been proved to be clinically active in patients to date. Different studies, with a small number of patients, tested the activity of trastuzumab with or without taxanes in PC patients. These trials failed to show significant antitumor activity of trastuzumab. However, they included unselected patients for HER2 expression, or HER2 was tested in primary hormone-dependent tumors or the studies were prematurely terminated due to the low percentage of HER2 overexpression observed [19] [20] [21] . More recently, two studies in nonselected patients for HER2 expression tested the activity of the HER dimerization inhibitor, pertuzumab in HIPC patients. One [22] tested two different doses of pertuzumab as a single agent in castrate chemotherapy-naive PC patients and reported absence of PSA responses. A second study [23] tested pertuzumab in HIPC patients after taxane-based therapy. While no PSA responses were observed, this group reported a significant percentage of patients with disease stabilization and a median survival time longer than that expected in this patients population. These authors suggested that even no PSA response was observed, and impact in survival cannot be excluded. At present, both predictive and surrogate markers for response to chemotherapy in PC patients are lacking. Updated analysis of the TAX 327 trial failed to identify predictive factors for response to docetaxel [38] . In that sense, the correlation between serum HER2 ECD and response to docetaxel is a nonpreviously reported observation and further investigation in this field is warranted.
Our work and previously published data indicate that about one-third of patients with metastatic HIPC overexpress HER2. Clinical trials with anti-HER2-targeted therapies in this specific patient population have not been conducted to date. Moreover, in these studies the activity of the tested drug has been evaluated based on PSA response criteria. It is not clear whether a potential interaction between HER2 signaling, AR activation and PSA transcription exists, and PSA would not be a reliable marker of antitumor activity. Moreover, based on our results, HER2 ECD levels may be a surrogate marker of HER2 overexpression in hormone-independent tumor cells and can be useful as a noninvasive strategy to select patients for these studies. However, a larger number of patients analyzed for serum HER2 ECD and HER2 tissue expression would be needed to confirm these data.
It is important to consider that the strong correlation observed between HER2 expression in tissue and elevation of HER2 ECD in serum may suggest that the predominant form of HER2 in prostate tumor cells would be the truncated form of the protein (p105). It may explain also, at least in part, the low activity of antibody-based therapies in PC, due to the lack of the extracellular ectodomain. Moreover, high levels of HER2 ECD have been associated with resistance to trastuzumab in breast cancer patients [39] . In that sense, the use of tyrosine kinase inhibitors, such as lapatinib, or the specific inhibition of HER2 ECD cleavage in combination with pertuzumab or trastuzumab [24, 26] may be interesting therapeutic strategies to investigate in HER2-overexpressing metastatic hormone-independent PC patients. 
